Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9E1T

CryoEM structure of LARGE1 bound to UDP-GlcA

Summary for 9E1T
Entry DOI10.2210/pdb9e1t/pdb
EMDB information47420
DescriptorXylosyl- and glucuronyltransferase LARGE1, MANGANESE (II) ION, URIDINE-5'-DIPHOSPHATE-GLUCURONIC ACID (3 entities in total)
Functional Keywordsglycosyltransferase, transferase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight180882.93
Authors
Joseph, S.,Spellmon, N.,Campbell, K.P. (deposition date: 2024-10-21, release date: 2025-02-12, Last modification date: 2025-10-22)
Primary citationJoseph, S.,Schnicker, N.J.,Spellmon, N.,Xu, Z.,Yan, R.,Yu, Z.,Davulcu, O.,Yang, T.,Hopkins, J.,Anderson, M.E.,Venzke, D.,Campbell, K.P.
LARGE1 processively polymerizes length-controlled matriglycan on prodystroglycan.
Nat Commun, 16:9028-9028, 2025
Cited by
PubMed Abstract: Matriglycan is a linear glycan (xylose-β1,3-glucuronate), which binds proteins in the extracellular matrix that contain laminin-globular domains and Lassa Fever Virus. It is indispensable for neuromuscular function. Matriglycan of insufficient length can cause muscular dystrophy with abnormal brain and eye development. LARGE1 (Like-acetylglucosaminyltransferase-1) uniquely synthesizes matriglycan on dystroglycan. The mechanism of matriglycan synthesis is not obvious from cryo-EM reconstructions of LARGE1. However, by reconstituting activity in vitro on recombinant prodystroglycan we show that the presence of the dystroglycan N-terminal domain (DGN), phosphorylated core M3, and a xylose-glucuronate primer are necessary for matriglycan polymerization by LARGE1. By introducing active site mutations, we demonstrate that LARGE1 processively polymerizes matriglycan on prodystroglycan, with its length regulated by the dystroglycan prodomain, DGN. Our enzymatic analysis of LARGE1 uncovers the mechanism of matriglycan synthesis on dystroglycan, which can form the basis for therapeutic strategies to treat matriglycan-deficient neuromuscular disorders and arenaviral infections.
PubMed: 41073435
DOI: 10.1038/s41467-025-64080-z
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3 Å)
Structure validation

247035

PDB entries from 2026-01-07

PDB statisticsPDBj update infoContact PDBjnumon